Special Issue "New Treatment Strategies for Chronic Kidney Disease"
Deadline for manuscript submissions: closed (30 November 2023) | Viewed by 164
Chronic kidney disease (CKD) affects around 10% of adults and continues to grow due to the continuous onset of obesity and diabetes. CKD is a significant risk factor for cardiovascular morbidity and mortality. Current treatment strategies include targeting blood pressure and albuminuria, avoiding nephrotoxins, and reducing cardiovascular risk. However, the number of patients reaching end-stage kidney disease (ESKD) is still increasing, although the death rate is high. Nephrology is a fast-moving science, such is the example of new treatments for diabetic kidney disease (DKD), including renin–angiotensin system blockers, sodium–glucose cotransport inhibitors (SGLT2i), and mineralocorticoid receptor antagonists (MRA). Furthermore, research has shown a strong rationale for SGLT2 inhibition to be used as a standard of care for most CKD patients, including those with non-diabetic kidney disease. Recent studies have shown that inflammation, myofibroblast activation, tissue hypoxia, cell loss, and extracellular matrix deposition lead to CKD. The translation of these findings from bench to bedside can improve the efficacy of treatments for CKD.
Nowadays, the development of effective therapies for CKD is an ongoing challenge, and the focus of this Special Issue is to cover all new lines of treatment for CKD, including regenerative therapies. By reflecting on the current state of knowledge in this area, the issue aims to contribute to a better understanding of the molecular mechanisms involved in CKD progression and how these can be targeted to slow or halt the progression of the disease. Ultimately, these advancements can improve the quality of life of patients with CKD and reduce the burden of this disease on healthcare systems worldwide.
Prof. Dr. Goce Spasovski
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- chronic kidney disease
- diabetes kidney disease
- cardiovascular risk